66 79

Cited 0 times in

Molecular biomarker testing for non-small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group

Authors
 Sunhee Chang  ;  Hyo Sup Shim  ;  Tae Jung Kim  ;  Yoon-La Choi  ;  Wan Seop Kim  ;  Dong Hoon Shin  ;  Lucia Kim  ;  Heae Surng Park  ;  Geon Kook Lee  ;  Chang Hun Lee 
Citation
 JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE, Vol.55(3) : 181-191, 2021-05 
Journal Title
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE
ISSN
 2383-7837 
Issue Date
2021-05
Keywords
Biomarker ; Carcinoma, non-small-cell lung ; Consensus ; Precision medicine
Abstract
Molecular biomarker testing is the standard of care for non-small cell lung cancer (NSCLC) patients. In 2017, the Korean Cardiopulmonary Pathology Study Group and the Korean Molecular Pathology Study Group co-published a molecular testing guideline which contained almost all known genetic changes that aid in treatment decisions or predict prognosis in patients with NSCLC. Since then there have been significant changes in targeted therapies as well as molecular testing including newly approved targeted drugs and liquid biopsy. In order to reflect these changes, the Korean Cardiopulmonary Pathology Study Group developed a consensus statement on molecular biomarker testing. This consensus statement was crafted to provide guidance on what genes should be tested, as well as methodology, samples, patient selection, reporting and quality control.
Files in This Item:
T202105379.pdf Download
DOI
10.4132/jptm.2021.03.23
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
Yonsei Authors
Shim, Hyo Sup(심효섭) ORCID logo https://orcid.org/0000-0002-5718-3624
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/187258
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links